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Purpose:  This  multicenter,  randomized,  open-label,  phase  II study  (JO19907)  compared  the  efﬁcacy  and
safety of  ﬁrst-line  carboplatin-paclitaxel  (CP)  alone  with  bevacizumab-CP  in  Japanese  patients  with
advanced  non-squamous  non-small-cell  lung  cancer  (NSCLC).
Methods:  Chemonaïve  patients  with  stage  IIIB,  IV  or  recurrent  non-squamous  NSCLC  were  eligible  for
participation.  Patients  were  randomly  assigned  in  a 2:1 ratio  to receive  bevacizumab-CP  or  CP  alone.
Chemotherapy  was  repeated  for up to 6  cycles  or until  disease  progression  or unacceptable  toxicity.
Bevacizumab  recipients  who  completed  ≥3  cycles  of  chemotherapy  could  continue  bevacizumab  as
monotherapy  until  disease  progression  or unacceptable  toxicity.  The  primary  endpoint  was  progression-
free  survival  (PFS).arboplatin
aclitaxel
dvanced lung cancer
hemonaïve
Results: After  conﬁrming  the  tolerability  of  bevacizumab-CP  in a  small  number  of patients,  180  patients
were  recruited,  of  whom  121  were  assigned  to  bevacizumab-CP  and  59  to  CP  alone.  Hazard  ratio  (HR)  for
PFS  was  0.61  with  bevacizumab-CP  versus  CP alone  (p = 0.0090;  median  6.9 versus  5.9  months).  Objective
response  rate  was  signiﬁcantly  higher  with  bevacizumab-CP  than  with  CP alone  (60.7%  versus  31.0%;
p  =  0.0013).  Median  overall  survival  was  >22  months  in  both  treatment  groups  (HR  0.99;  p  = 0.9526).  No
new safety  signals  were  detected.
∗ Corresponding author at: Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577 Japan.
el.:  +81 4 7133 1111; fax: +81 4 7131 9960.
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Conclusion:  Study  JO19907  met  its primary  endpoint,  demonstrating  that  the  addition  of  bevacizumab  to
ﬁrst-line  CP signiﬁcantly  improves  PFS  in  Japanese  patients  with  advanced  non-squamous  NSCLC.  This
prolonged  PFS  by bevacizumab  did  not  translate  into  OS  beneﬁt  with  the extremely  longer  underlying
survival  compared  to  historical  data.  No  new  safety  signals  were  identiﬁed  in  this  population.  (Japan
Pharmaceutical  Information  Center  [JAPIC]  registration  number:  CTI-060338).
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puted tomography, magnetic resonance imaging, or x-ray using
RECIST 1.0. PFS, the primary endpoint of this study, and responses. Introduction
Bevacizumab is a humanized monoclonal antibody that specif-
cally targets vascular endothelial growth factor, inhibiting
ngiogenesis, thereby impeding tumor growth and survival. In
rials that recruited mainly Western populations, bevacizumab
iven with ﬁrst-line chemotherapy and continued as monother-
py until disease progression has been shown to be effective in
atients with non-squamous non-small-cell lung cancer (NSCLC).
 phase III trial (E4599) performed in patients with non-squamous
SCLC, which was conducted primarily in the USA, demon-
trated that the addition of bevacizumab (15 mg/kg) to ﬁrst-line
arboplatin-paclitaxel (CP) signiﬁcantly prolonged overall sur-
ival (OS; hazard ratio [HR] 0.79; p = 0.003) [1].  That pivotal trial
as of particular clinical signiﬁcance given that bevacizumab
xtended median OS beyond the historic 8-month benchmark
chieved with conventional platinum-based chemotherapy [2].
n a second phase III trial (AVAiL), which was  conducted princi-
ally in European patients with non-squamous NSCLC, addition of
evacizumab (7.5 or 15 mg/kg) to another commonly-used ﬁrst-
ine chemotherapy regimen (cisplatin-gemcitabine) signiﬁcantly
mproved progression-free survival (PFS [HR] 0.75; p = 0.003) [3].
While bevacizumab has been robustly evaluated in Western
opulations, its efﬁcacy and tolerability have not been investi-
ated in Japanese patients with NSCLC. It is important that targeted
gents that are established in Western patients are also studied
n Japanese patients, as ethnic differences may  inﬂuence response
o treatment and safety proﬁles. This has been highlighted in
everal recent studies reporting that Asian patients may  respond
ifferently to targeted agents compared with Western patients,
or example, epidermal growth factor receptor inhibitors (EGFR-
KIs) such as erlotinib and geﬁtinib have been associated with
mproved responses in Asian patients with NSCLC [4,5]. Espe-
ially, in Japanese patients with NSCLC the frequency of EGFR
utations is higher (40% or more) compared with Western popu-
ations, and in Japanese population with EGFR mutations, geﬁtinib
howed improved PFS compared to conventional chemotherapies
n the ﬁrst line treatment setting [6,7]. In addition, prospective
omparisons of CP therapy between three randomized phase III
tudies have suggested that chemonaïve Japanese patients with
SCLC have prolonged OS and PFS, with this chemotherapy than
S patients [6].  This may  be due to differences in genotypic distri-
ution of genes involved in paclitaxel disposition or DNA damage
epair [8],  and further highlights the importance of evaluating can-
er treatments in different ethnic populations.
We  report the ﬁnal results of the randomized phase II study
O19907 in Japan, the only study in Asia which compared the efﬁ-
acy and safety of ﬁrst-line CP with or without bevacizumab in
atients with advanced non-squamous NSCLC.
. Patients and methods
JO19907 was a multicenter, randomized, open-label, phase II
tudy conducted at 19 sites in Japan. The protocol was  approved
y the institutional review boards of all participating centers and
as conducted in accordance with the Declaration of Helsinki
nd Guideline for Good Clinical Practices. All patients provided© 2011 Elsevier Ireland Ltd. 
written informed consent prior to any study-speciﬁc procedures
being performed.
2.1. Patients
Eligible patients were aged 20–74 years and had histologi-
cally or cytologically documented stage IIIB with pleural and/or
pericardial effusion and/or pleural dissemination, IV or recurrent
non-squamous NSCLC. Patients were also required to have: mea-
surable lesions as deﬁned by Response Evaluation Criteria in Solid
Tumors (RECIST 1.0);[9] an Eastern Cooperative Oncology Group
Performance Status (ECOG PS) of 0 or 1; life expectancy of ≥3
months; and adequate bone marrow, hepatic, and renal function.
Key exclusion criteria were: prior chemotherapy for NSCLC; cen-
tral nervous system metastases or spinal cord compression; a
tumor invading major blood vessels or with cavitation; hemoptysis
(≥2.5 mL  per event); history of coagulation disorders or therapeutic
anticoagulation; uncontrolled hypertension; or history of a symp-
tomatic lung disorder.
2.2. Study design
The study was conducted in two steps. Step 1 was  performed to
evaluate the tolerability of bevacizumab-CP in Japanese patients.
In this step, six patients received bevacizumab-CP intravenously
on day 1 of a 21-day cycle. Carboplatin was administered at
a dose calculated to produce an area-under-the-curve (AUC) of
6 mg/(mL min), paclitaxel was administered at a dose of 200 mg/m2
and bevacizumab at a dose of 15 mg/kg. AEs were assessed based
on the National Cancer Institute Common Terminology Criteria for
Adverse Events (NCI-CTCAE) v3.0. Transition to step 2 of the trial
was  possible if no more than two patients presented during the
ﬁrst treatment cycle with grade 4 hematologic toxicities or grade
≥3 non-hematologic toxicities.
In step 2, eligible patients were randomly assigned in a 2:1 ratio
to receive bevacizumab-CP or CP alone with no placebo for beva-
cizumab. Randomization was  performed centrally and patients
were stratiﬁed according to disease stage (IIIB, IV, or recurrent),
ECOG PS, and gender. All treatments were administered on day 1
of a 21-day cycle according to the regimens described in step 1.
Chemotherapy was repeated every 21 days for a total of 6 cycles
unless there was  evidence of disease progression or unacceptable
toxicity. In the absence of disease progression, patients who were
treated with bevacizumab and who completed at least 3 cycles
of chemotherapy could continue with bevacizumab monotherapy
until disease progression or unacceptable toxicity.
2.3. Efﬁcacy and safety assessments
After the baseline evaluation, tumor lesions were evaluated
every 6 weeks for the ﬁrst 18 weeks, thereafter every 9 weeks until
evidence of disease progression. Responses were assessed by com-
Open access under CC BY-NC-ND license.were assessed by an Independent Review Committee in a blind
manner. AEs were monitored throughout the study and graded
using NCI-CTCAE v3.0.
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Table 1
Summary of baseline patient characteristics and demographics.
Variable CP (n = 59) Bevacizumab-CP
(n = 121)
Median age, years (range) 60 (38–73) 61 (34–74)
Age <65 years, n (%) 40 (68%) 73 (60%)
Age ≥65 years, n (%) 19 (32%) 48 (40%)
Gender, n (%)
Male 38 (64%) 77 (64%)
Female 21 (36%) 44 (36%)
ECOG PS, n (%)
0 29 (49%) 62 (51%)
1 30 (51%) 59 (49%)
Tumor histology, n (%)
Adenocarcinoma 55 (93%) 111 (92%)
Large cell carcinoma 2 (3%) 2 (2%)
Other 2 (3%) 8 (7%)
Stage, n (%)
IIIB 12 (20%) 28 (23%)
IV 42 (71%) 83 (69%)
Recurrent 5 (8%) 10 (8%)
Smoking status, n (%)
Never smoker 19 (32%) 38 (31%)
Current or past smoker 40 (68%) 83 (69%)
CI: 4.2–6.5), respectively. In the subgroup analyses, improvement
in PFS with bevacizumab-CP was evident in most patient subgroups
assessed (Fig. 3).64 S. Niho et al. / Lung C
.4. Pharmacokinetic assessments
Blood samples were collected prior to and 1 h after every
nfusion of bevacizumab until the sixth cycle from patients
andomized to bevacizumab-CP. The pharmacokinetic proﬁle of
evacizumab was characterized using non-linear regression by
tting a one-compartment model to bevacizumab serum concen-
rations (WinNonlin v4.1; Pharsight, St. Louis, MO). The following
arameters were estimated: clearance (CL); volume of distribution
Vd); half-life (t½), AUC from zero to inﬁnity (AUCinf) and mean
esidence time (MRT).
.5. Statistical analysis
PFS was deﬁned as the time from randomization to ﬁrst doc-
mented disease progression or death, whichever occurred ﬁrst.
econdary endpoints included OS, objective response rate (ORR),
ime to response, duration of response, disease control rate (DCR;
um of complete responses plus partial responses plus stable
isease), pharmacokinetics, and safety. Efﬁcacy analyses were per-
ormed on eligible patients who underwent tumor evaluation at
east once after the baseline assessment. Safety analyses were per-
ormed on all patients who received at least one dose of study
reatment.
On the basis of the PFS beneﬁt reported in E4599 (HR 0.66;
 < 0.001) [1],  it was estimated that addition of bevacizumab to CP
ould reduce the risk of disease progression by 35%. Given this
ssumption, an HR point-estimate for PFS of 0.8 or better could be
aken to indicate a treatment difference similar to that observed in
4599. The study was designed to have an 86.8% conditional prob-
bility to detect an effect on PFS similar to that found in E4599. The
FS analysis was  planned after 130 events; therefore, to allow for
vent and drop-out rates, the trial enrolled 180 patients.
Time-to-event distributions were estimated by the
aplan–Meier method. Between-treatment differences at each
ime-to-event endpoint were tested with a two-sided stratiﬁed
og-rank test adjusted with the stratiﬁcation factors used for
andomization. HRs were calculated by Cox proportional-hazards
ethods adjusted with the stratiﬁcation factors for randomization.
xploratory forward stepwise regression analyses with the use of
he Cox model were performed to adjust for treatment effect on
FS.
. Results
Patients were enrolled between April 2007 and March 2008.
he clinical data cut-off dates were November 2008 for analy-
is of the primary endpoint (PFS), February 2009 for analysis of
he safety and February 2010 for analysis of the secondary end-
oint (OS). As planned, six patients were enrolled in step 1 of the
tudy. None of the predeﬁned toxicities were reported in these six
atients.
.1. Patient characteristics
A total of 180 patients were recruited to step 2 of the study:
21 were assigned to bevacizumab-CP (Fig. 1). Three patients were
xcluded from the safety and efﬁcacy analyses as they did not begin
reatment due to ineligibility conﬁrmed, clinically unacceptable
igh total dose of carboplatin calculated, or withdrawn consent,
nd a further two patients were excluded from the efﬁcacy anal-
sis because they did not have measurable disease. Table 1 shows
elected demographic and baseline characteristics of all randomly
ssigned patients. The two groups were well balanced at base-
ine.CP, carboplatin plus paclitaxel; ECOG, Eastern Cooperative Oncology Group; PS,
performance status.
3.2. Treatment
The median number of chemotherapy cycles was 6 in the
bevacizumab-CP group and 4.5 in the CP group. After initial
bevacizumab-CP treatment of between 3 and 6 cycles, 72 patients
(60.5%) received bevacizumab monotherapy for a median of 6
cycles (range 1–25).
3.3. Efﬁcacy analysis
The HR for PFS with bevacizumab-CP versus CP alone was 0.61
(95% CI: 0.42–0.89; p = .0090; Fig. 2); median PFS in the two  treat-
ment groups was 6.9 months (95% CI: 6.1–8.3) and 5.9 months (95%Fig. 1. Enrollment, randomization and follow-up of patients.
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Table 2
Best tumor response in evaluable patients according to RECIST.
CP (n = 58) Bevacizumab-CP
(n = 117)
CR, n (%) 0 1 (0.9%)
PR, n (%) 18 (31.0%) 70 (59.8%)
SD, n (%) 23 (39.7%) 39 (33.3%)
PD, n (%) 14 (24.1%) 5 (4.3%)
Non-evaluable, n (%) 3 (5.2%) 2 (1.7%)
ORR, % (95% CI) 31.0% (19.5–44.5) 60.7% (51.2–69.6)a
DCR, % (95% CI) 70.7% (57.3–81.9) 94.0% (88.1–97.6)b
CP, carboplatin plus paclitaxel; CR, complete response; PR, partial response; SD,
stable disease; PD, progressive disease; ORR, objective response rate, DCR, disease
control rate.
a p = 0.0013 versus CP (Cochran–Mantel–Haenszel test adjusted with the stratiﬁ-
cation factors used for randomization).
b p = 0.0002 versus CP (Cochran–Mantel–Haenszel test adjusted with the stratiﬁ-Fig. 2. Kaplan–Meier estimate of PFS and OS.
ORR was signiﬁcantly higher with bevacizumab-CP than with
P alone (60.7% [95% CI: 51.2–69.6%] versus 31.0% [95% CI:
9.5–44.5%], respectively; p = 0.0013) (Table 2) as was  the DCR
94.0% [95% CI: 88.1–97.6%] versus 70.7% [95% CI: 57.3–81.9%],
 = 0.0002) (Table 2).
puorgbuSyrogetaC
Haz
All
<65
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All
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Stage III B
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0
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-1 0 
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ECOG, Eastern Coopera tive Oncology Group;  P
Fig. 3. HRs (95% CI) for PFS, accorcation factors used for randomization).
The median time to response was shorter with bevacizumab-
CP (1.4 months; 95% CI: 1.4–1.5) than with CP alone (2.7 months;
95% CI: 1.4–2.8); however, this difference was not statistically sig-
niﬁcant (HR 1.45; 95% CI: 0.85–2.48; p = 0.1496). In addition, the
median duration of response was longer in bevacizumab-CP recip-
ients (6.9 months; 95% CI: 4.8–7.7) than in those treated with CP
alone (5.6 months; 95% CI: 5.1–8.3), with an HR of 0.80 (95% CI:
0.43–1.48; p = 0.4727).
The HR for OS with bevacizumab-CP versus CP alone was 0.99
(95% CI: 0.65–1.50; p = 0.9526; Fig. 2). The median OS was 22.8
months (95% CI: 18.1–28.2) in the bevacizumab-CP group, com-
pared with 23.4 months (95% CI: 17.4–28.5) in the CP alone group.
Most patients in both treatment groups received post-study thera-
pies (82% in bevacizumab-CP and 86% in CP alone). The number of
patients who  received third line therapy was  higher in the CP alone
group (48% in bevacizumab-CP and 57% in CP alone). EGFR-TKIs and
docetaxel were the main drugs in second and third lines of therapy,
administered to over 40% of patients (EGFR-TKIs: 41% and 47% in
bevacizumab-CP and in CP alone, respectively; docetaxel: 42% and
40%) (Table 3).
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Table  3
Post-protocol therapies (second line, third line).
Post-protocol therapy CP (n = 58) Bevacizumab-CP
(n = 117)
Second line chemotherapy 86% 82%
Third line chemotherapy 57% 48%
Treatment
docetaxel 40% 42%
EGFR-TKIs 47% 41%
gemcitabine 26% 24%
cisplatin 10% 9%
pemetrexed 5% 9%
C
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Cinvestigational agent 17% 3%
P, carboplatin plus paclitaxel; EFFR-TKIs, epidermal growth factor receptor
nhibitors.
.4. Safety analysis
Table 4 shows the incidences of AEs of special interest (i.e., AEs
hat have been associated with bevacizumab in combination with
hemotherapy in previous studies) observed in both treatment
roups.
Neutropenia was the most frequent AE of special interest in both
reatment groups. Rates of any-grade proteinuria were higher in the
evacizumab treatment arm, but were generally mild-to-moderate
n severity. Likewise, any-grade nasal bleeding occurred more fre-
uently with bevacizumab-CP; however, no grade ≥3 events were
eported.
While grade ≥3 hypertension was not reported in any patients
reated with CP alone, it occurred in 11% of bevacizumab-CP
ecipients. No grade 4 hypertension was observed. Grade ≥3
eukopenia, neutropenia, and hyponatremia were modestly higher
ith bevacizumab-CP than with CP alone. Febrile neutropenia
ccurred in 8% of patients in the bevacizumab-CP group compared
ith 7% of patients in the CP alone group (Table 4).
Grade 1–2 hemoptysis was reported in 22% of patients treatedith bevacizumab-CP compared with 5% of patients with CP alone.
here were no grade 3 or 4 hemoptysis events; however, one
rade 5 hemoptysis event was reported in a patient treated with
evacizumab-CP. This patient was male and had histology of
able 4
elected adverse events of special interest associated with carboplatin-paclitaxel ± bevac
Event CP (n = 58) 
Grade 1/2 Grade 3 
Hematologic toxicity
Leukopenia 48% 40% 
Neutropenia 9% 28% 
Decreased hemoglobin 76% 3% 
Thrombocytopenia 59% 3% 
Febrile neutropenia – 7% 
Non-hematologic toxicity
Hypertension 10% 0 
Bleeding 31% 0 
Hemoptysis 5% 0 
Nasal  bleeding 12% 0 
Venous thromboembolism 0 3% 
Arterial thromboembolism 0 0 
Congestive heart disease 2% 0 
Proteinuria 17% 0 
Fatigue 53% 0 
Vomiting 31% 0 
Neuropathy 81% 5% 
Muscle pain 71% 0 
Joint  pain 79% 0 
Elevated AST 36% 0 
Elevated ALT 36% 5% 
Hyponatremia 3% 0 
Treatment-related death 
a One grade 5 hemoptysis event was reported in the bevacizumab group.
P, carboplatin plus paclitaxel; AST, aspartate aminotransferase; ALT, alanine aminotrans 76 (2012) 362– 367
adenocarcinoma with the primary tumor located in the left lower
lobe and lymph-node metastases in the hilum of the left lung. The
tumor did not have any cavitation. The patient had no complicat-
ing disease or any history of hemoptysis or bloody sputum and was
not receiving anticoagulation therapy. The patient presented with
grade 5 hemoptysis on day 12 of the second cycle.
Discontinuation of chemotherapy due to AEs occurred slightly
more frequently in the bevacizumab-CP group (33% versus 26%
of patients receiving CP alone). Twenty-six percent of patients
discontinued bevacizumab because of an AE, mainly proteinuria,
neutropenia, or hemoptysis.
3.5. Pharmacokinetic analysis
Pharmacokinetic parameters were analyzed in 51 patients
who  received bevacizumab-CP. Bevacizumab had a mean CL of
2.92 ± 0.56 mL/day/kg, a mean t½ of 11.3 ± 2.1 days, a mean Vd of
46.51 ± 6.79 mL/kg, a mean AUCinf of 5,314 ± 1013 g day/mL and
an MRT  of 16.3 ± 3.0 days. The pharmacokinetic proﬁle of beva-
cizumab in JO19907 was similar to that reported in patients treated
with bevacizumab-CP in a US phase II study [10] (data not shown).
4. Discussion
In this phase II study, bevacizumab in combination with ﬁrst-
line CP in Japanese patients with non-squamous NSCLC reduced the
hazard of disease progression by 39% (HR 0.61; 95% CI: 0.42–0.89).
Furthermore, almost all evaluable patients who received beva-
cizumab achieved a tumor response or disease stabilization
compared with only three-quarters of those who  did not receive
bevacizumab. This study was  an open randomized trial and a poten-
tial bias could have been introduced by the use of non-blinded
medication. Taking into consideration the nature of PFS as end-
point and non-placebo-controlled study design, tumor responses
were evaluated by an Independent Review Committee in a blind
manner.
Median PFS with bevacizumab-CP in JO19907 was  6.9 months,
similar to that reported in phase III trials in Western populations
(6.2 months with bevacizumab-CP [1] and 6.5–6.7 months with
izumab therapy.
Bevacizumab-CP (n = 119)
Grade 4 Grade 1/2 Grade 3 Grade 4
2% 44% 46% 4%
57% 5% 18% 73%
5% 73% 10% 2%
5% 67% 4% <1%
0 – 8% 0
0 37% 11% 0
0 77% <1% 0
0 22% 0 0*
0 72% 0 0
0 4% 0 0
0 0 0 <1%
0 0 0 <1%
0 51% <1% 0
0 49% 3% 0
0 34% 2% 0
0 80% 8% 0
0 70% 0 0
0 81% <1% 0
0 44% 2% <1%
0 44% 3% <1%
0 6% 7% <1%
0% <1%a
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evacizumab-cisplatin-gemcitabine [3]). The magnitude of reduc-
ion in the hazard of disease progression in this study with addition
f bevacizumab to chemotherapy (HR 0.61) is also similar to, or
reater than, that reported in the Western phase III studies (HR 0.66
n E4599 [1] and 0.75–0.82 in AVAiL [3]). Furthermore, subgroup
nalyses according to baseline patient characteristics indicated
hat bevacizumab was effective in most patient subgroups stud-
ed. This conﬁrms the clinical activity of bevacizumab in Japanese
atients with non-squamous NSCLC. Therefore, extrapolating the
ata from Western populations, bevacizumab could be considered
s a ﬁrst-line treatment option for Japanese patients presenting
ith non-squamous NSCLC.
No new safety signals were reported for bevacizumab in
O19907. The favorable tolerability proﬁle of bevacizumab is
eﬂected in the observation that 60.5% of patients were able to
ontinue on bevacizumab monotherapy for a median of 6 cycles
ollowing chemotherapy. The incidences of grade ≥3 leukope-
ia, neutropenia, and hypertension were modestly higher in
atients treated with bevacizumab; however, the majority of
hese events were controlled with standard clinical management.
rade 4 neutropenia occurred signiﬁcantly more frequently with
evacizumab-CP than CP alone (73% versus 57%; p = 0.0395); how-
ver, there was no trend for an increased rate of febrile neutropenia
r other infection in bevacizumab treated patients. Interestingly,
he rate of grade 4 neutropenia in both groups was  higher than
hat seen in the E4599 study (25.5% in bevacizumab-CP and 16.8%
n CP alone) [1].  This supports the ﬁndings of Gandara et al., who
eported that grade 4 neutropenia is more common in Japanese
atients than Western patients treated with CP [8].
Although one grade 5 episode of hemoptysis did occur in the
evacizumab-CP group; overall hemoptysis events occurred at a
ate similar to or lower than those reported in the E4599 and AVAiL
tudies, with all but one of these events grade 1 or 2 in severity. In
ddition to excluding patients with a history of hemoptysis, as in
he E4599 study, the AVAiL and JO19907 studies excluded patients
ith tumors invading major blood vessels. Moreover, because ret-
ospective analysis [11] of the E4599 study and another US phase
I study [10] indicated that tumor cavitation is a potential risk
actor for pulmonary hemorrhage in patients treated with beva-
izumab plus chemotherapy, the eligibility criteria of this study
lso excluded patients with cavitated tumors. Appropriate selec-
ion of eligible patients might have made the risk of hemoptysis
linically manageable.
Unfortunately, the PFS improvement conferred by bevacizumab
id not translate into an OS beneﬁt in this study, which may  be
ue to several limitations. Firstly, this study was  not sufﬁciently
owered to assess the OS beneﬁt of bevacizumab plus CP, which
as a secondary endpoint. Also, the median survival times were
22 months in both arms, approximately double the median sur-
ival time observed in the E4599 study, which undoubtedly reﬂects
he unexpectedly long post-progression survival (PPS) [12] due to
he efﬁcacy of post-protocol therapies. It has been reported that
hen PPS is long, statistical power to detect a difference in OS
s greatly reduced and that lack of statistically signiﬁcant differ-
nce in OS does not imply lack of OS beneﬁt [13]. In our trial, more
han 80% of the patients received subsequent therapies, compared
ith less than 50% in E4599. Moreover, many newly developed efﬁ-
acious drugs with proven survival beneﬁt, such as EGFR-TKIs or
ocetaxel, were used in the post-study period. Taking into con-
ideration the higher frequency of EGFR mutations in Japanese
atients, especially, use of EGFR-TKIs could contribute to the pro-
onged PPS. Thus, our second limitation is that we were unable to
horoughly collect and report information on the second- or third-
ine therapies used in this trial, including treatment duration and
umor responses to those post-protocol therapies. In addition, nei-
her investigation nor report of the EGFR mutation status was not
[
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required in this trial. More detailed analyses on post-protocol ther-
apies might be necessary to evaluate the OS beneﬁt in future study
reports.
In conclusion, addition of bevacizumab to ﬁrst-line CP results
in similar PFS beneﬁts in Japanese patients with advanced non-
squamous NSCLC as in Western patients. No new safety concerns
were raised in Japanese population.
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